[Rectal Cancer: Organ preservation and neoadjuvant treatment escalation].
Cancer du rectum : préservation d’organe et escalade du traitement néo-adjuvant.
Antineoplastic Agents
/ administration & dosage
Chemoradiotherapy
Chemotherapy, Adjuvant
/ statistics & numerical data
Humans
Neoadjuvant Therapy
/ methods
Neoplasm Recurrence, Local
/ surgery
Organ Sparing Treatments
Radiotherapy Dosage
Rectal Neoplasms
/ therapy
Rectum
/ surgery
Salvage Therapy
Watchful Waiting
Cancer du rectum
Chimioradiothérapie
Exérèse locale
Local excision
Organ preservation
Préservation d’organe
Radiochemotherapy
Rectal cancer
Watch and wait
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
02
09
2021
accepted:
17
09
2021
pubmed:
23
11
2021
medline:
17
12
2021
entrez:
22
11
2021
Statut:
ppublish
Résumé
Standard treatment consisting of chemoradiotherapy followed by radical surgery with total mesorectal excision, results in good oncologic local control but high morbidity and poor functional results. Since chemoradiotherapy results in 15% pathological complete response, even reaching up to 30% in case of association with neoadjuvant chemotherapy, radical surgery has been recently debated for good responders. Therefore, a de-escalation strategy, by omitting radical surgery in good responders, has recently been developed with two different options: a watch and wait strategy, requiring an accurate clinical and radiological definition of complete response and a local excision strategy including patients with sub-complete response. Ongoing trials focus on response optimization by chemotherapy intensification or radiotherapy dose escalation. However, many questions are still to be answered regarding definition of complete response, follow-up strategy, morbidity of salvage surgery in case of recurrence as well as long-term oncological and functionnal results.
Identifiants
pubmed: 34802716
pii: S0007-4551(21)00391-X
doi: 10.1016/j.bulcan.2021.09.007
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
1126-1131Informations de copyright
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.